Romiplostim biosimilar - GENERIUM Pharmaceuticals
Alternative Names: GNR-069Latest Information Update: 05 Jul 2024
At a glance
- Originator GENERIUM Pharmaceuticals
- Class Antianaemics; Carrier proteins; Immunotherapies; Recombinant fusion proteins; Skin disorder therapies
- Mechanism of Action Thrombopoietin receptor agonists; Thrombopoietin stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Idiopathic thrombocytopenic purpura
Most Recent Events
- 03 Apr 2024 GENERIUM completes a phase III trial in Idiopathic thrombocytopenic purpura (In adults, In the elderly) in Russia (SC) (NCT05492409)
- 19 Oct 2023 GENERIUM Pharmaceuticals completes a phase III trial in Idiopathic thrombocytopenic purpura (In adults, In the elderly) in Russia (SC) (NCT05220878)
- 28 Mar 2022 GENERIUM initiates enrolment in the phase-III clinical trials in Idiopathic thrombocytopenic purpura (In adults, In the elderly) in Russia (SC) (NCT05492409)